We are live on ! Find out more

LB Pharmaceuticals

LBRX

Market cap $1.36B

42.01 USD

+3.92

10.29%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

42.50

+0.49

1.17%

1 day

10.29%

5 days

3.57%

1 month

22.62%

3 months

-12.81%

6 months

31.28%

Year to date

105.53%

1 year

170.86%

5 years

142.83%

10 years

142.83%

About: LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Employees: 27

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Strengthened leadership with the appointment of Susan G. Kozauer, M.D.

LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

LB Pharmaceuticals NASDAQ: LBRX outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The company said it expects three clinical readouts over the next three years, beginning with Phase III schizophrenia data in the first half of 2027.

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

LB Pharmaceuticals to Participate in Upcoming Investor Events

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences:

LB Pharmaceuticals to Participate in Upcoming Investor Events

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. The event will feature Roger S.

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment

LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity

LB Pharmaceuticals earns a buy rating, with a base case valuation of $85 per share and potential upside to $150 if Phase 3 and clinical differentiation succeed. LB-102's N-methyl modification enables effective brain receptor occupancy at much lower doses than amisulpride, supporting once-daily dosing and potentially fewer side effects. The main investment debate centers on whether the R-enantiomer's 5-HT7 activity delivers unique clinical benefits beyond D2/D3 antagonism, which remains unproven.

LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G.

LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.

Investors Business Daily

IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?

LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.

IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?

LB Pharmaceuticals to Participate in Upcoming September Investor Events

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:

LB Pharmaceuticals to Participate in Upcoming September Investor Events

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer.

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

See News Rankings

Price charts implemented using Lightweight Charts™